April

Insights+ Key Biosimilars Events of April 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC’s approval for …

Insights+ Key Biosimilars Events of April 2021 Read More »

The key IT decisions that helped providers survive April 2020

As Covid-19 cases started escalating last April, providers in hotspot states, like New York, California and Washington, had to quickly pivot their IT plans. These are some of the decisions that five health IT leaders made — aside from expanding telehealth — that helped their health systems survive the first wave of the pandemic and …

The key IT decisions that helped providers survive April 2020 Read More »